Phase II trial of pembro & epacadostat in patients with recurrent clear cell carcinoma of the ovary

Phase II trial of pembro & epacadostat in patients with recurrent clear cell carcinoma of the ovaryПодробнее

Dr. Hamid on Epacadostat Plus Pembrolizumab in Advanced MelanomaПодробнее

Combined PD1 and IDO1 inhibiton in patients with clear cell carcinoma of the ovaryПодробнее

Dr. Kardosh Discusses Epacadostat in Gastric/GEJ AdenocarcinomaПодробнее

What’s the Latest in Clear Cell Ovarian Cancer?Подробнее

Dr. Markman Discusses the Olaparib Phase II TrialПодробнее

Dr. Lara on Epacadostat Plus Pembrolizumab in RCCПодробнее

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomasПодробнее

Exploring the Combination of Epacadostat and Pembrolizumab in Urothelial CarcinomaПодробнее

How do clinical trials work for ovarian cancer? What is the process?Подробнее

Dr. Grisham Discusses Start of Phase 2 Trial on Investigational RAF/MEK Inhibitor in Ovarian CancerПодробнее

Phase II Results for Niraparib in Heavily Pretreated Patients With Ovarian CancerПодробнее

Rare Ovarian Cancers: Challenges, Treatment Advances, Clinical TrialsПодробнее

Dr. Moore on the NOVA Trial for Ovarian CancerПодробнее

Dr. Karasic on Phase II Trial of Nivolumab and IpilimumabПодробнее

Advances in Immunology in Ovarian CancerПодробнее

2019 GOC AGM - Session IIIПодробнее

Dr. Tara Gangadhar on Epacadostat/ Pembrolizumab CombinationПодробнее

2023 Ovarian Cancer Symposium - A/Prof Kelly Bolton (Washington, US)Подробнее